|
40 mg (N=9) |
40 mg (N=9) |
80 mg (N=8) |
80 mg (N=8) |
Placebo (N=6) |
Placebo
(N=6) |
|
n (%) |
m |
n (%) |
m |
n (%) |
m |
Infections and infestations |
3 (33.3%) |
3 |
2 (25.0%) |
2 |
0 |
0 |
Nasopharyngitis |
3 (33.3%) |
3 |
2 (25.0%) |
2 |
0 |
0 |
Respiratory, thoracic and mediastinal disorders |
1 (11.1%) |
1 |
3 (37.5%) |
3 |
1 (16.7%) |
1 |
Nasal congestion |
0 |
0 |
2 (25.0%) |
2 |
1 (16.7%) |
1 |
Epistaxis |
0 |
0 |
1 (12.5%) |
1 |
0 |
0 |
Oropharyngeal pain |
1 (11.1%) |
1 |
0 |
0 |
0 |
0 |
Nervous system disorders |
0 |
0 |
4 (50.0%) |
17 |
0 |
0 |
Somnolence |
0 |
0 |
2 (25.0%) |
8 |
0 |
0 |
Disturbance in attention |
0 |
0 |
1 (12.5%) |
7 |
0 |
0 |
Headache |
0 |
0 |
1 (12.5%) |
1 |
0 |
0 |
Tremor |
0 |
0 |
1 (12.5%) |
1 |
0 |
0 |
General disorders and administration site conditions |
0 |
0 |
1 (12.5%) |
1 |
0 |
0 |
Fatigue |
0 |
0 |
1 (12.5%) |
1 |
0 |
0 |
Musculoskeletal and connective tissue disorders |
1 (11.1%) |
2 |
0 |
0 |
0 |
0 |
Musculoskeletal pain |
1 (11.1%) |
1 |
0 |
0 |
0 |
0 |
Pain in extremity |
1 (11.1%) |
1 |
0 |
0 |
0 |
0 |